Candel Therapeutics Inc (NASDAQ: CADL) kicked off on Friday, up 21.89% from the previous trading day, before settling in for the closing price of $4.14. Over the past 52 weeks, CADL has traded in a range of $0.77-$14.30.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company slipped by -25.00% over the past five years. While this was happening, its average annual earnings per share was recorded -25.95%. With a float of $19.99 million, this company’s outstanding shares have now reached $29.21 million.
Let’s look at the performance matrix of the company that is accounted for 42 employees. In terms of profitability, gross margin is 54.28%, operating margin of -2001.58%, and the pretax margin is -2939.13%.
Candel Therapeutics Inc (CADL) Insider Updates
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Candel Therapeutics Inc is 38.46%, while institutional ownership is 14.75%. The most recent insider transaction that took place on Oct 11 ’24, was worth 90,750. In this transaction 10% Owner of this company sold 15,000 shares at a rate of $6.05, taking the stock ownership to the 944,873 shares. Before that another transaction happened on Oct 14 ’24, when Company’s 10% Owner sold 15,000 for $6.02, making the entire transaction worth $90,300. This insider now owns 929,873 shares in total.
Candel Therapeutics Inc (CADL) Performance Highlights and Predictions
Wall Street market experts anticipate that the next fiscal year will bring earnings of 0 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -25.95% per share during the next fiscal year.
Candel Therapeutics Inc (NASDAQ: CADL) Trading Performance Indicators
Take a look at Candel Therapeutics Inc’s (CADL) current performance indicators. Last quarter, stock had a quick ratio of 1.18.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.74, a number that is poised to hit -0.30 in the next quarter and is forecasted to reach 0.15 in one year’s time.
Technical Analysis of Candel Therapeutics Inc (CADL)
Candel Therapeutics Inc (NASDAQ: CADL) saw its 5-day average volume 0.75 million, a negative change from its year-to-date volume of 1.79 million. As of the previous 9 days, the stock’s Stochastic %D was 38.22%. Additionally, its Average True Range was 0.44.
During the past 100 days, Candel Therapeutics Inc’s (CADL) raw stochastic average was set at 27.61%, which indicates a significant decrease from 70.31% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 110.39% in the past 14 days, which was higher than the 75.86% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $5.82, while its 200-day Moving Average is $5.68. Nevertheless, the first resistance level for the watch stands at $5.68 in the near term. At $6.31, the stock is likely to face the second major resistance level. The third major resistance level sits at $7.06. If the price goes on to break the first support level at $4.30, it is likely to go to the next support level at $3.55. Assuming the price breaks the second support level, the third support level stands at $2.92.
Candel Therapeutics Inc (NASDAQ: CADL) Key Stats
The company with the Market Capitalisation of 199.50 million has total of 32,476K Shares Outstanding. Its annual sales at the moment are 0 K in contrast with the sum of -37,940 K annual income. Company’s last quarter sales were recorded 0 K and last quarter income was -10,650 K.
